The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NTRK1 gene fusions as a novel oncogene target in lung cancer.
Robert Charles Doebele
Consultant or Advisory Role - Pfizer
Honoraria - Abbott Molecular
Research Funding - Pfizer
Aria Vaishnavi
No relevant relationships to disclose
Marzia Capelletti
No relevant relationships to disclose
Anh T. Le
No relevant relationships to disclose
Severine Kako
No relevant relationships to disclose
Mohit Butaney
No relevant relationships to disclose
Sakshi Mahale
No relevant relationships to disclose
Dara L. Aisner
Honoraria - Abbott Molecular; Pfizer
Julia Haas
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Steven W. Andrews
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Doron Lipson
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Philip J. Stephens
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Marileila Varella-Garcia
Consultant or Advisory Role - Pfizer
Honoraria - Abbott Molecular
Pasi Antero Janne
No relevant relationships to disclose
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine